5-Azacytidine treatment inhibits the development of lung cancer models via epigenetic reprogramming and activation of cellular pathways with anti-tumor activity

Raluca Munteanu; Cristian Moldovan; Adrian Bogdan Țigu; Rareş Drulă; Richard Feder; Lorand Magdo; Ancuța Jurj; Lajos Ráduly; Liviuța Budișan; Radu Pîrlog; Alin Moldovan; Alina‐Andreea Zimța; Elena Ioana Braicu; Alexandra Preda; V.C. Munteanu; Mihai Romitan; Diana Gulei; Tudor‐Eliade Ciuleanu

doi:10.15386/mpr-2777

Abstract

Non-small cell lung cancer (NSCLC) treatment is challenged by late detection and limited therapeutic options. Aberrant DNA methylation, a common epigenetic alteration in NSCLC, offers new therapeutic avenues. This study aims to evaluate the combined effects of 5-Azacytidine (5-Aza), an epigenetic modifier, and ionizing radiation (IR) on NSCLC, exploring the underlying molecular mechanisms and therapeutic potential.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Munteanu et al. (2024) studied this question.

synapsesocial.com/papers/68e579d7b6db6435875199d9 https://doi.org/10.15386/mpr-2777

View Full Paper

Ask AI

Bookmark

Share

5-Azacytidine treatment inhibits the development of lung cancer models via epigenetic reprogramming and activation of cellular pathways with anti-tumor activity

Abstract

Discussion

Cite This Study

5-Azacytidine treatment inhibits the development of lung cancer models via epigenetic reprogramming and activation of cellular pathways with anti-tumor activity

Abstract

Discussion

Cite This Study

Keep reading

Keep reading